Journal of Pediatrics Review

Published by: Kowsar
Corrected Proof scheduled for 6 (2)

The Role of Immune System in Thalassemia Major: A Narrative Review

Ali Bazi 1 , 2 , Iraj Shahramian 2 , Hajar Yaghoobi 3 , Majid Naderi 4 and Hakim Azizi 5 , *
Authors Information
1 Clinical Research Development Unit, Amir-Al-Momenin Hospital, Zabol University of Medical Sciences, Zabol, IR Iran
2 Pediatric Digestive and Hepatic Diseases Research Center, Zabol University of Medical Sciences, Zabol, IR Iran
3 Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, IR Iran
4 Genetics of Non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
5 Department of Medical Parasitology, Zabol University of Medical Sciences, Zabol, IR Iran
Article information
  • Journal of Pediatrics Review: , In Press (In Press); e14508
  • Published Online: October 3, 2017
  • Article Type: Review Article
  • Received: June 5, 2017
  • Revised: August 1, 2017
  • Accepted: August 23, 2017
  • DOI: 10.5812/jpr.14508

To Cite: Bazi A, Shahramian I, Yaghoobi H, Naderi M, Azizi H. et al. The Role of Immune System in Thalassemia Major: A Narrative Review, J Pediatr Rev. Online ahead of Print ;In Press(In Press):e14508. doi: 10.5812/jpr.14508.

Abstract
Copyright: Copyright © 2017, Journal of Pediatrics Review. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Footnotes
References
  • 1. Bazi A, Miri-Moghaddam E, Moudi Z. The High Birth Rate of Thalassemia Major and the Associated Problems in Sistan and Baluchistan Province, Iran. Gene Cell Tissue. 2016; 3(4)
  • 2. Bazi A, Miri-Moghaddam E. Spectrum of β-thalassemia Mutations in Iran, an Update. Iran J Pediatr Hematol& Oncol. 2016; 6(3)
  • 3. Shahraki-Vahed A, Firouzkouhi M, Abdollahimohammad A, Ghalgaie J. Lived experiences of Iranian parents of beta-thalassemia children. J Multidiscip Healthc. 2017; 10: 243-51[DOI][PubMed]
  • 4. Bazi A, Mirimoghaddam E, Rostami D, Dabirzadeh M. Characteristics of Seropositive Hepatitis B and C Thalassemia Major Patients in South-East of Iran. Biotechnol Health Sci. 2016; 3(2)
  • 5. Elsayh KI, Mohammed WS, Zahran AM, Saad K. Leukocytes apoptosis and adipocytokines in children with beta thalassemia major. Clin Exp Med. 2016; 16(3): 345-50
  • 6. Ghaffari J, Vahidshahi K, Kosaryan M, Parvinnejad N, Mahdavi M, Karami H. Nitroblue tetrazolium test in patients with beta-thalassemia major. Saudi Med J. 2008; 29(11): 1601-5[PubMed]
  • 7. Kyriakou DS, Alexandrakis MG, Kyriakou ES, Liapi D, Kourelis TV, Passam F, et al. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol. 2001; 80(10): 577-83[PubMed]
  • 8. Amer J, Fibach E. Chronic oxidative stress reduces the respiratory burst response of neutrophils from beta-thalassaemia patients. Br J Haematol. 2005; 129(3): 435-41[DOI][PubMed]
  • 9. Walter PB, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, et al. Increased leucocyte apoptosis in transfused beta-thalassaemia patients. Br J Haematol. 2013; 160(3): 399-403[DOI][PubMed]
  • 10. Atasever B, Ertan NZ, Erdem-Kuruca S, Karakas Z. In vitro effects of vitamin C and selenium on NK activity of patients with beta-thalassemia major. Pediatr Hematol Oncol. 2006; 23(3): 187-97[DOI][PubMed]
  • 11. Atasever Arslan B, Erdem-Kuruca S, Karakas Z, Erman B, Ergen A. Effects of micro environmental factors on natural killer activity (NK) of beta thalassemia major patients. Cell Immunol. 2013; 282(2): 93-9[DOI][PubMed]
  • 12. Gharagozloo M, Karimi M, Amirghofran Z. Double-faced cell-mediated immunity in beta-thalassemia major: stimulated phenotype versus suppressed activity. Ann Hematol. 2009; 88(1): 21-7[DOI][PubMed]
  • 13. Pratummo K, Jetsrisuparb A, Fucharoen S, Tripatara A. Hepcidin expression from monocyte of splenectomized and non-splenectomized patients with HbE-beta-thalassemia. Hematology. 2014; 19(3): 175-80[DOI][PubMed]
  • 14. Ozturk O, Yaylim I, Aydin M, Yilmaz H, Agachan B, Demiralp E, et al. Increased plasma levels of interleukin-6 and interleukin-8 in beta-thalassaemia major. Haematologia (Budap). 2001; 31(3): 237-44[PubMed]
  • 15. El-Rasheidy FH, Essa ES, Mahmoud AA, Nada Ael W. Elevated serum adiponectin is related to elevated serum ferritin and interleukin-6 in beta-thalassaemia major children. J Pediatr Endocrinol Metab. 2016; 29(8): 953-8[DOI][PubMed]
  • 16. Ghatreh-Samani M, Esmaeili N, Soleimani M, Asadi-Samani M, Ghatreh-Samani K, Shirzad H. Oxidative stress and age-related changes in T cells: is thalassemia a model of accelerated immune system aging? Cent Eur J Immunol. 2016; 41(1): 116-24[DOI][PubMed]
  • 17. Al-Awadhi AM, Alfadhli SM, Al-Khaldi D, Borhama M, Borusly M. Investigation of the distribution of lymphocyte subsets and zinc levels in multitransfused beta-thalassemia major patients. Int J Lab Hematol. 2010; 32(2): 191-6[DOI][PubMed]
  • 18. Zahran AM, Elsayh KI, Saad K, Embaby M, Ali AM. Regulatory B cells (CD19(+)CD38(hi)CD24(hi)) in alloimmunized and non-alloimmunized children with beta-thalassemia major. Blood Cells Mol Dis. 2016; 57: 91-6[DOI][PubMed]
  • 19. Ghaffari J, Vahidshahi K, Kosaryan M, Soltantooyeh Z, Mohamadi M. Humoral immune system state in ss thalassemia major. Med Glas (Zenica). 2011; 8(2): 192-6[PubMed]
  • 20. Tourkantoni N, Athanassiou-Metaxa M, Zafiriou D, Tzimouli V, Economou M, Taparkou A, et al. Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment. Hemoglobin. 2008; 32(1-2): 35-40[DOI][PubMed]
  • 21. Pattanapanyasat K, Thepthai C, Lamchiagdhase P, Lerdwana S, Tachavanich K, Thanomsuk P, et al. Lymphocyte subsets and specific T-cell immune response in thalassemia. Cytometry. 2000; 42(1): 11-7[PubMed]
  • 22. Pourgheysari B, Karimi L, Beshkar P. Alteration of T Cell Subtypes in Beta-Thalassaemia Major: Impact of Ferritin Level. J Clin Diagn Res. 2016; 10(2)-8[DOI][PubMed]
  • 23. Walker EJ, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci. 2000; 30(4): 354-65[PubMed]
  • 24. Bao W, Zhong H, Yazdanbakhsh K. Immunologic characterization suggests reduced alloimmunization in a murine model of thalassemia intermedia. Transfusion. 2014; 54(11): 2880-91[DOI][PubMed]
  • 25. Noulsri E, Lerdwana S, Fucharoen S, Pattanapanyasat K. Phenotypic characterization of circulating CD4/CD8 T-lymphocytes in beta-thalassemia patients. Asian Pac J Allergy Immunol. 2014; 32(3): 261-9[DOI][PubMed]
  • 26. Bozdogan G, Erdem E, Demirel GY, Yildirmak Y. The role of Treg cells and FoxP3 expression in immunity of beta-thalassemia major AND beta-thalassemia trait patients. Pediatr Hematol Oncol. 2010; 27(7): 534-45[DOI][PubMed]
  • 27. Corthay A. How do regulatory T cells work? Scand J Immunol. 2009; 70(4): 326-36[DOI][PubMed]
  • 28. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010; 10(7): 490-500[DOI][PubMed]
  • 29. Consolini R, Calleri A, Legitimo A, Massei F. Immunological evaluation of patients with beta-thalassemia major. Acta Haematol. 2001; 105(1): 7-12[PubMed]
  • 30. Swe KM, Abas AB, Bhardwaj A, Barua A, Nair NS. Zinc supplements for treating thalassaemia and sickle cell disease. Cochrane Database Syst Rev. 2013; (6)[DOI][PubMed]
  • 31. Erdogan E, Canatan D, Ormeci AR, Vural H, Aylak F. The effects of chelators on zinc levels in patients with thalassemia major. J Trace Elem Med Biol. 2013; 27(2): 109-11[DOI][PubMed]
  • 32. Tienboon P. Effect of nutrition support on immunity in paediatric patients with beta-thalassaemia major. Asia Pac J Clin Nutr. 2003; 12(1): 61-5[PubMed]
  • 33. Gharagozloo M, Karimi M, Amirghofran Z. Immunomodulatory effects of silymarin in patients with beta-thalassemia major. Int Immunopharmacol. 2013; 16(2): 243-7[DOI][PubMed]
  • 34. Gharagozloo M, Bagherpour B, Tahanian M, Oreizy F, Amirghofran Z, Sadeghi HM, et al. Premature senescence of T lymphocytes from patients with beta-thalassemia major. Immunol Lett. 2009; 122(1): 84-8[DOI][PubMed]
  • 35. Hsu HC, Scott DK, Mountz JD. Impaired apoptosis and immune senescence - cause or effect? Immunol Rev. 2005; 205: 130-46[DOI][PubMed]
  • 36. Ozdemir ZC, Koc A, Aycicek A, Kocyigit A. N-Acetylcysteine supplementation reduces oxidative stress and DNA damage in children with beta-thalassemia. Hemoglobin. 2014; 38(5): 359-64[DOI][PubMed]
  • 37. Al-Sweedan SA, Khabour O, Isam R. Genotoxicity assessment in patients with thalassemia minor. Mutat Res. 2012; 744(2): 167-71[DOI][PubMed]
  • 38. Alidoost F, Gharagozloo M, Bagherpour B, Jafarian A, Sajjadi SE, Hourfar H, et al. Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients. Int Immunopharmacol. 2006; 6(8): 1305-10[DOI][PubMed]
  • 39. Sari TT, Gatot D, Akib AA, Bardosono S, Hadinegoro SR, Harahap AR, et al. Immune response of thalassemia major patients in Indonesia with and without splenectomy. Acta Med Indones. 2014; 46(3): 217-25[PubMed]
  • 40. Al-Ofairi BA, Barakat AB, Ghanim Hel D, Shehata IH, El-Sayed MH. A study of innate and adaptive immune responses in beta-thalassemic patients with chronic hepatitis C virus infection. Egypt J Immunol. 2011; 18(1): 61-76[PubMed]
  • 41. Darzi AA, Kamali S, Khakzad M. Influence of splenectomy on immunoglobulins and complement components in major thalassemia. Caspian J Intern Med. 2015; 6(1): 30-3[PubMed]
  • 42. Kiani-Amin M, Daneshi M, Ayazi P, Mohammadian S, Rezaei N. Serum immunoglobulin levels in splenectomized and non- splenectomized patients with major Beta-thalassemia. Iran J Pediatr. 2011; 21(1): 95-8[PubMed]
  • 43. Kadymova EA. [The features of immune status of major beta-thalassemia patients during various periods after splenectomy]. Georgian Med News. 2009; (174): 39-44[PubMed]
  • 44. Kadimova E. [Immune system of splenectomized thalassemia patients in different periods after splenectomy]. Georgian Med News. 2007; (151): 47-52[PubMed]
  • 45. Banyatsuppasin W, Butthep P, Atichartakarn V, Thakkinstian A, Archararit N, Pattanapanyasat K, et al. Activation of mononuclear phagocytes and its relationship to asplenia and phosphatidylserine exposing red blood cells in hemoglobin E/beta-thalassemia patients. Am J Hematol. 2011; 86(1): 89-92[DOI][PubMed]
  • 46. Ardalan FA, Osquei MR, Toosi MN, Irvanloo G. Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study. BMC Gastroenterol. 2004; 4: 17[DOI][PubMed]
  • 47. Lai ME, Origa R, Danjou F, Leoni GB, Vacquer S, Anni F, et al. Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur J Haematol. 2013; 90(6): 501-7[DOI][PubMed]
  • 48. Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A, et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica. 2012; 97(5): 679-86[DOI][PubMed]
  • 49. Cachem F, Dias AS, Monteiro C, Castro JR, Fernandes G, Delphim L, et al. The proportion of different interleukin-17-producing T-cell subsets is associated with liver fibrosis in chronic hepatitis C. Immunology. 2017; 151(2): 167-76[DOI][PubMed]
  • 50. Crane M, Tennakoon S, Harman A, Torresi J, Avihingsanon A, Lewin S. Intrahepatic CXCL-10 is strongly associated with markers of liver fibrosis in HIV-HBV co-infection. Eur J Immunol. 2016; 46: 688-9
  • 51. Rajanayagam JK, Haller W, Debray D, Verkade HJ, Mclin VA, Evans HM, et al. Serum autoantibodies are associated with chronic hepatitis and graft fibrosis after pediatric liver transplantation. Hepatology. 2015; 62: 1051A
  • 52. Fasbender F, Widera A, Hengstler JG, Watzl C. Natural Killer Cells and Liver Fibrosis. Front Immunol. 2016; 7: 19[DOI][PubMed]
  • 53. Khawar MB, Azam F, Sheikh N, Abdul Mujeeb K. How Does Interleukin-22 Mediate Liver Regeneration and Prevent Injury and Fibrosis? J Immunol Res. 2016; 2016: 2148129[DOI][PubMed]
  • 54. Sadeghian MH, Keramati MR, Badiei Z, Ravarian M, Ayatollahi H, Rafatpanah H, et al. Alloimmunization among transfusion-dependent thalassemia patients. Asian J Transfus Sci. 2009; 3(2): 95-8[DOI][PubMed]
  • 55. Azarkeivan A, Ansari S, Ahmadi MH, Hajibeigy B, Maghsudlu M, Nasizadeh S, et al. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol. 2011; 28(6): 479-85[DOI][PubMed]
  • 56. Seferi I, Xhetani M, Face M, Burazeri G, Nastas E, Vyshka G. Frequency and specificity of red cell antibodies in thalassemia patients in Albania. Int J Lab Hematol. 2015; 37(4): 569-74[DOI][PubMed]
  • 57. Bao W, Zhong H, Li X, Lee MT, Schwartz J, Sheth S, et al. Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and beta-thalassemia major. Am J Hematol. 2011; 86(12): 1001-6[DOI][PubMed]
  • 58. Yu J, Heck S, Yazdanbakhsh K. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am J Hematol. 2007; 82(8): 691-6[DOI][PubMed]
  • 59. Najafian N, Chitnis T, Salama AD, Zhu B, Benou C, Yuan X, et al. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest. 2003; 112(7): 1037-48[DOI][PubMed]
  • 60. Kang JH, Park BR, Kim KS, Kim DY, Huh HJ, Chae SL, et al. Beta-thalassemia minor is associated with IgA nephropathy. Ann Lab Med. 2013; 33(2): 153-5[DOI][PubMed]
  • 61. Kadam PP, Manglani MV, Sharma SM, Sharma RA, Setia MS. Immunoglobulin levels and CD4 / CD8 counts in beta- thalassemia major. Indian Pediatr. 2014; 51(12): 1000-2[PubMed]
  • 62. Shahramian I, Dehghani SM, Haghighat M, Noori NM, Teimouri AR, Sharafi E, et al. Serologic evaluation of celiac disease in patients with beta thalassemia major and control. Gastroenterol Hepatol Bed Bench. 2015; 8(2): 153-9[PubMed]
  • 63. Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit. 2003; 9(1)-22[PubMed]
  • 64. Wiener E. Impaired phagocyte antibacterial effector functions in beta-thalassemia: a likely factor in the increased susceptibility to bacterial infections. Hematology. 2003; 8(1): 35-40[DOI][PubMed]
  • 65. Mallat ME, Sharara AI. Treatment and prevention of hepatitis B and C in thalassemia. Hemoglobin. 2009; 33 Suppl 1-44[DOI][PubMed]
  • 66. Celis R, Torre-Martinez G, Torre-Amione G. Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy? Curr Opin Cardiol. 2008; 23(3): 254-60[DOI][PubMed]
  • 67. Vasdev S, Stuckless J, Richardson V. Role of the immune system in hypertension: modulation by dietary antioxidants. Int J Angiol. 2011; 20(4): 189-212[DOI][PubMed]
  • 68. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011; 108(9): 1133-45[DOI][PubMed]
  • 69. Lai ME, Vacquer S, Carta MP, Spiga A, Cocco P, Abete C, et al. Evidence for a proatherogenic biochemical phenotype in beta thalassemia minor and intermedia. Acta Haematol. 2011; 126(2): 87-94[DOI][PubMed]
  • 70. Gulhan B, Yalcin E, Unal S, Oguz B, Ozcelik U, Ersoz DD, et al. Effects of blood transfusion on cytokine profile and pulmonary function in patients with thalassemia major. Clin Respir J. 2016; 10(2): 153-62[DOI][PubMed]
  • 71. Monge L, Pinach S, Caramellino L, Bertero MT, Dall'omo A, Carta Q. The possible role of autoimmunity in the pathogenesis of diabetes in B-thalassemia major. Diabetes Metab. 2001; 27(2 Pt 1): 149-54[PubMed]
  • 72. Miller J, Popiel J, Chelmonska-Soyta A. Humoral and Cellular Immune Response in Canine Hypothyroidism. J Comp Pathol. 2015; 153(1): 28-37[DOI][PubMed]
  • 73. Terpos E, Voskaridou E. Interactions between osteoclasts, osteoblasts and immune cells: implications for the pathogenesis of bone loss in thalassemia. Pediatr Endocrinol Rev. 2008; 6 Suppl 1: 94-106[PubMed]
  • 74. Miri-Moghaddam E, Bahrami S, Naderi M, Bazi A, Karimipoor M. Xmn1-158 gammaGVariant in B-Thalassemia Intermediate Patients in South-East of Iran. Int J Hematol Oncol Stem Cell Res. 2017; 11(2): 165-71[PubMed]
  • 75. Chan NC, Lau KM, Cheng KC, Chan NP, Ng MH. A Multi-locus Approach to Characterization of Major Quantitative Trait Loci Influencing Hb F Regulation in Chinese beta-thalassemia Carriers. Hemoglobin. 2016; 40(6): 400-4[DOI][PubMed]
  • 76. Mejri A, Siala H, Ouali F, Bibi A, Messaoud T. Identification of candidate genes involved in clinical variability among Tunisian patients with beta-thalassemia. Gene. 2012; 506(1): 166-72
  • 77. Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Haematol. 2016; 172(4): 512-23[DOI][PubMed]
  • 78. Montaser LM, El-Rashidi FH, Essa ES, Azab SM. Analysis of CD177 neutrophil expression in beta-thalassemia patients. APMIS. 2011; 119(10): 674-80[DOI][PubMed]
  • 79. Ramos P, Casu C, Gardenghi S, Breda L, Crielaard BJ, Guy E, et al. Macrophages support pathological erythropoiesis in polycythemia vera and beta-thalassemia. Nat Med. 2013; 19(4): 437-45[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader